產(chǎn)品訂購信息：
英文名稱  Anti-RNF11 

中文名稱   環(huán)指蛋白11抗體品牌 

別    名  CGI 123; RING finger protein 11; RNF11; RNF11_HUMAN; Sid 1669; SID1669.

濃    度   1mg/1ml

規(guī) 格  0.2ml/200μg

抗體來源   Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Chicken, Dog, Cow, Horse, Rabbit, Sheep 

產(chǎn)品類型   一抗  

研究領(lǐng)域    細胞生物 免疫學(xué) 表觀遺傳學(xué)

蛋白分子量  predicted molecular weight: 11kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from human RNF11 

亞    型   IgG

純化方法   affinity purified by Protein A

儲 存 液   Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4

環(huán)指蛋白11抗體品牌 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:50-200

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 

Function : Essential component of a ubiquitin-editing protein complex, comprising also TNFAIP3, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. Promotes the association of TNFAIP3 to RIPK1 after TNF stimulation. TNFAIP3 deubiquitinates 'Lys-63' polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Recruits STAMBP to the E3 ubiquitin-ligase SMURF2 for ubiquitination, leading to its degradation by the 26S proteasome.

Subunit : Interacts (when phosphorylated) with 14-3-3. Interacts with the E3 ubiquitin-ligases NEDD4, ITCH, SMURF2 and WWP1 (By similarity). Also interacts with the E2 ubiquitin-conjugating enzymes UBE2D1 and UBE2N, but neither with CDC34, nor with UBE2L3. Interacts with ZNF350, EPS15 and STAMBP. After TNF stimulation, interacts with TAX1BP1, TNFAIP3 and RIPK1; these interaction are transient and they are lost after 1 hour of stimulation with TNF (By similarity). Interacts with GGA1.

Subcellular Location : Cytoplasm. Nucleus. Predominantly cytoplasmic, when unphosphorylated, and nuclear, when phosphorylated by PKB/AKT1.

Tissue Specificity : Expressed at low levels in the lung, liver, kidney, pancreas, spleen, prostate, thymus, ovary, small intestine, colon, and peripheral blood lymphocytes, and, at intermediate levels, in the testis, heart, brain and placenta. Highest expression in the skeletal muscle. In the brain, expressed at different levels in several regions: high levels in the amygdala, moderate in the hippocampus and thalamus, low in the caudate and extremely low levels in the corpus callosum (at protein level). Restricted to neurons, enriched in somatodendritic compartments and excluded from white matter (at protein level). In substantia nigra, present in cell bodies and processes of dopaminergic and nondopaminergic cells (at protein level). In Parkinson disease, sequestered in Lewy bodies and neurites. Overexpressed in breast cancer cells, but not detected in the surrounding stroma and weakly, if at all, in normal breast epithelial cells (at protein level). Also expressed in several tumor cell lines.

Post-translational modifications : Ubiquitinated in the presence of ITCH, or SMURF2, and UBE2D1, as well as WWP1.

Phosphorylation by PKB/AKT1 may accelerate degradation by the proteasome.

May be acylated at Cys-4, possibly palmitoylated. Acylation at both Gly-2 and Cys-4 is required for proper localization to the endosomes.

Similarity : Contains 1 RING-type zinc finger.

Database links : UniProtKB/Swiss-Prot: Q9Y3C5.1

NF-κBp50(p50 NF-kappa B;p50NFKB) 細胞核因子50/κ基因結(jié)合核因子50抗原Multi-class antibodies規(guī)格： 0.5mg

Anti-APOH 載脂蛋白H抗體Multi-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh phospho-ATXN1(Ser775) 磷酸化失調(diào)癥蛋白1抗體 規(guī)格 0.1ml

品名 規(guī)格 備注

Vesicle docking protein p115 英文名稱： 囊泡對接蛋白p115抗體 0.2ml

DAZL 英文名稱： 細胞發(fā)育相關(guān)蛋白DAZL抗體 0.2ml

Anti-APOH 載脂蛋白H抗體Multi-class antibodies規(guī)格： 0.2ml

Anti-PIM1/FITC 熒光素標記前病毒整合位點蛋白1抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rabbit Anti-human Gamma-chain 兔抗人γ-鏈 (親和層析純化)Multi-class antibodies規(guī)格： 0.2mg

代謝型谷氨酸受體2 Anti-GRM2 0.2ml

Dog IgM/APC APC標記的兔抗犬IgM抗體 0.1ml

FAM155A 英文名稱： FAM155A蛋白抗體 0.2ml

Rhesus antibody Rh Phospho-SEK1/MKK4 (Ser257) 磷酸化原活化蛋白激酶激酶4抗體 規(guī)格 0.1ml

Rabbit Anti-human Gamma-chain 兔抗人γ-鏈 (親和層析純化)Multi-class antibodies規(guī)格： 0.2mg

Phospho-MEK4 (Thr261) 英文名稱： 磷酸化原活化蛋白激酶激酶4抗體 0.1ml

EDG6 英文名稱： 內(nèi)皮細胞的分化蛋白6抗體 0.1ml

T淋巴細胞負調(diào)節(jié)蛋白之一抗體 Anti-VSIG4 Antibody 0.2ml

Anti-TSHR/FITC 熒光素標記促甲狀腺素受體抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh phospho-IKK beta(Tyr199) 磷酸化KB抑制蛋白激酶β抗體 規(guī)格 0.1ml

Caspase-12(hunman) 半胱胺酸蛋白酶蛋白-12抗原(人)Multi-class antibodies規(guī)格： 0.5mg

HUM, 正常人主動脈平滑肌細胞

GES-1 人胃粘膜細胞

SELE Others Rat 大鼠 E-selectin / ELAM-1 / CD62E 人細胞裂解液 (陽性對照)

CM-M038小鼠肝內(nèi)膽管上皮細胞完全培養(yǎng)基100mL

上皮細胞培養(yǎng)基PEpiCM

EB病毒轉(zhuǎn)化的人B淋巴細胞;KMY0910 真皮成纖維細胞完全培養(yǎng)基 100mL

CL-0063CNE(人細胞)5×106cells/瓶×2

ST6GALNAC2 Others Mouse 小鼠 STHM / ST6GALNAC2 人細胞裂解液 (陽性對照)

小鼠小腸粘膜上皮細胞完全培養(yǎng)基 100mL

EC9706人細胞 Human esophageal cancer cell line EC9706. DMEM+10%FBS

IL6 Protein Human 重組人 IL6 / Ierleukin-6 蛋白

SF763(人細胞) 5×106cells/瓶×2 J82(細胞)

環(huán)指蛋白11抗體品牌 HUM, 正常人主動脈平滑肌細胞

GES-1 人胃粘膜細胞

SELE Others Rat 大鼠 E-selectin / ELAM-1 / CD62E 人細胞裂解液 (陽性對照)

CM-M038小鼠肝內(nèi)膽管上皮細胞完全培養(yǎng)基100mL

上皮細胞培養(yǎng)基PEpiCM

EB病毒轉(zhuǎn)化的人B淋巴細胞;KMY0910 真皮成纖維細胞完全培養(yǎng)基 100mL

抗體的生物素化標記實驗要點：

1. 環(huán)指蛋白11抗體品牌 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件；

3.用NHSB量過量也是不利的,抗原的結(jié)合位點可能因此被封閉,導(dǎo)致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；

5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點時,或位于酶的催化位點時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；

6.生物素還可能與不同的功能基團,如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價結(jié)合；

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；

8.在細胞的熒光標記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細胞可導(dǎo)致高本底。

抗體的鑒定：

1）環(huán)指蛋白11抗體品牌 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴散試驗來鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力?？贵w的特異性高,它的識別能力就強。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。